Arshad Khanani, MD

Articles by Arshad Khanani, MD

Arshad Khanani, MD, on Comparing Wet AMD Gene Therapy 4D-150 to Aflibercept in a Randomized Clinical Trial

March 11th 2024

The assistant professor in the department of pediatrics at the University of Florida College of Medicine discussed also discussed the latest results announced from the phase 2 portion of the PRISM study.

Arshad Khanani, MD, on Future Plans for anti-VEGF Gene Therapy 4D-150

ByArshad Khanani, MD

May 11th 2023

The director of clinical research at Sierra Eye Associates discussed 4D Molecular Therapeutics’ plans for 4D-150 in both wet AMD and diabetic macular edema.

Arshad Khanani, MD, on 4D-150’s Ability to Address Treatment Burden in Wet AMD

ByArshad Khanani, MD

May 9th 2023

The director of clinical research at Sierra Eye Associates discussed the latest results from a clinical trial evaluating 4D Molecular Therapeutics’ gene therapy, 4D-150, that were presented at ARVO’s 2023 conference.

Arshad Khanani, MD, on Restoring Aflibercept Expression in Wet AMD With Gene Therapy

ByArshad Khanani, MD

January 17th 2023

The director of clinical research at Sierra Eye Associates discussed data from the phase 1/2 PRISM study.

Arshad Khanani, MD, on Reducing Treatment Burden in Wet AMD With Gene Therapy

ByArshad Khanani, MD

December 1st 2022

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.

Arshad Khanani, MD

Articles by Arshad Khanani, MD

Arshad Khanani, MD, on Comparing Wet AMD Gene Therapy 4D-150 to Aflibercept in a Randomized Clinical Trial

Arshad Khanani, MD, on Future Plans for anti-VEGF Gene Therapy 4D-150

Arshad Khanani, MD, on 4D-150’s Ability to Address Treatment Burden in Wet AMD

Arshad Khanani, MD, on Restoring Aflibercept Expression in Wet AMD With Gene Therapy

Arshad Khanani, MD, on Reducing Treatment Burden in Wet AMD With Gene Therapy

Latest Updated Articles

Trending on CGTlive®

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK

Around the Helix: Cell and Gene Therapy Company Updates – October 22, 2025

AskBio’s Heart Failure Gene Therapy AB-1002 Shows Ability to Improve NYHA Class in Phase 1 Trial